KRAS

Chr 12AD

KRAS proto-oncogene, GTPase

Also known as: 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

Arteriovenous malformation of the brain, somaticMIM #108010
Bladder cancer, somaticMIM #109800
Breast cancer, somaticMIM #114480
Cardiofaciocutaneous syndrome 2MIM #615278
AD
Gastric cancer, somaticMIM #613659
Leukemia, acute myeloid, somaticMIM #601626
Lung cancer, somaticMIM #211980
Noonan syndrome 3MIM #609942
AD
Oculoectodermal syndrome, somaticMIM #600268
Pancreatic carcinoma, somaticMIM #260350
RAS-associated autoimmune leukoproliferative disorderMIM #614470
AD
Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaicMIM #163200
UniProtLeukemia, juvenile myelomonocytic
382
ClinVar variants
72
Pathogenic / LP
0.00
pLI score
12
Active trials
Clinical SummaryKRAS
🧬
Gene-Disease Validity (ClinGen)
cardiofaciocutaneous syndrome · ADStrong

Strong evidence — appropriate for clinical testing

3 total gene-disease associations curated

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
72 Pathogenic / Likely Pathogenic· 120 VUS of 382 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.24LOEUF
pLI 0.001
Z-score 1.06
OE 0.63 (0.341.24)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
2.32Z-score
OE missense 0.34 (0.260.45)
33 obs / 97.4 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.63 (0.341.24)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.34 (0.260.45)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.93
01.21.6
LoF obs/exp: 6 / 9.5Missense obs/exp: 33 / 97.4Syn Z: 0.34

ClinVar Variant Classifications

382 submitted variants in ClinVar

Classification Summary

Pathogenic37
Likely Pathogenic35
VUS120
Likely Benign144
Benign28
Conflicting18
37
Pathogenic
35
Likely Pathogenic
120
VUS
144
Likely Benign
28
Benign
18
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
11
26
0
37
Likely Pathogenic
0
26
9
0
35
VUS
3
89
24
4
120
Likely Benign
0
1
73
70
144
Benign
0
0
27
1
28
Conflicting
18
Total312715975382

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

KRAS · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

KRAS-related cardiofaciocutaneous syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkin
G2P ↗

KRAS-related Noonan syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkin
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Arteriovenous malformation of the brain, somatic

MIM #108010

Molecular basis of disorder known

Bladder cancer, somatic

MIM #109800

Molecular basis of disorder known

Breast cancer, somatic

MIM #114480

Molecular basis of disorder known

Cardiofaciocutaneous syndrome 2

MIM #615278

Molecular basis of disorder known

Autosomal dominant

Gastric cancer, somatic

MIM #613659

Molecular basis of disorder known

Leukemia, acute myeloid, somatic

MIM #601626

Molecular basis of disorder known

Lung cancer, somatic

MIM #211980

Molecular basis of disorder known

Noonan syndrome 3

MIM #609942

Molecular basis of disorder known

Autosomal dominant

Oculoectodermal syndrome, somatic

MIM #600268

Molecular basis of disorder known

Pancreatic carcinoma, somatic

MIM #260350

Molecular basis of disorder known

RAS-associated autoimmune leukoproliferative disorder

MIM #614470

Molecular basis of disorder known

Autosomal dominant

Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic

MIM #163200

Molecular basis of disorder known

📖
GeneReview available — KRAS
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

RECRUITING
NCT06947811Phase PHASE1, PHASE2Sun Yat-sen UniversityStarted 2025-06-09
AlmonertinibPalbociclib
Allergic Rhinitis

Integrative Omics Approach to Allergic Rhinitis

ACTIVE NOT RECRUITING
NCT03324100Medical University of GrazStarted 2018-04-01
Colorectal CancerChemotherapy Effect

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

RECRUITING
NCT05797467Phase PHASE3Sixth Affiliated Hospital, Sun Yat-sen UniversityStarted 2023-04-01
FOLFOX chemotherapy regimensBevacizumab
Gastric CancerHealthy

Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

RECRUITING
NCT05991947Zhejiang Cancer HospitalStarted 2021-03-01
No intervention
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid Adenocarcinoma

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

ACTIVE NOT RECRUITING
NCT05276973Phase PHASE1National Cancer Institute (NCI)Started 2022-09-08
BiopsyCarboplatinIpatasertib
Healthy Pregnant WomenObese Pregnant WomenGestational Diabetes

Pregnancy Cohort Study: Pregnancy as a Window to Future Health

RECRUITING
NCT06925815Medical University of GrazStarted 2023-07-27
Rectal Neoplasms

MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer

RECRUITING
NCT03714490Phase PHASE2Cancer Institute and Hospital, Chinese Academy of Medical SciencesStarted 2018-10-23
SCPRTCRTCAPOX
EGFR NP_005219.2:p.S492RKRAS Gene MutationMAP2K1 Gene Mutation

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

ACTIVE NOT RECRUITING
NCT03087071Phase PHASE2M.D. Anderson Cancer CenterStarted 2017-12-29
Laboratory Biomarker AnalysisPanitumumabTrametinib
Neovascular Age-related Macular Degeneration

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

RECRUITING
NCT07007065Phase PHASE3AbbVieStarted 2025-11-05
Surabgene Lomparvovec (ABBV-RGX-314)Ranibizumab Control
Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

RECRUITING
NCT07409272Phase PHASE3Astellas Pharma Global Development, Inc.Started 2026-02-17
SetidegrasibOxaliplatinLeucovorin
Tumor, Solid

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

RECRUITING
NCT06484790Phase PHASE1Ting DengStarted 2024-04-08
NW-301VNW-301D
Acute Coronary Syndrome

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

ACTIVE NOT RECRUITING
NCT05754957Phase PHASE3Janssen Research & Development, LLCStarted 2023-04-07
MilvexianPlacebo